Paolo Dellabona

11PUBLICATIONS
62CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyMolecular targetsCancer diagnosisApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Oct 01, 2024
CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms.

Xin Zhou, Ying Wang, Zhangqi Dou

|Jun 18, 2024
Author Correction: IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity.

Elisa Landoni, Mark G Woodcock, Gabriel Barragan

|Jan 03, 2024
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity.

Elisa Landoni, Mark G Woodcock, Gabriel Barragan

|Sep 08, 2023
Fasting mimicking diet in mice delays cancer growth and reduces immunotherapy-associated cardiovascular and systemic side effects.

S Cortellino, V Quagliariello, G Delfanti

|Jun 23, 2023
Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma.

Giuseppina Arbore, Luca Albarello, Gabriele Bucci

|Aug 19, 2022
TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells.

Gloria Delfanti, Filippo Cortesi, Alessandra Perini

Pageof 2

Frequent Collaborators

8 joint publications

Paolo Dellabona

3 joint publications

Mark G Woodcock

3 joint publications

Gianpietro Dotti

2 joint publications

Gabriele Casirati